ZVRA's Quality Score fell 3 points on Tue, Nov 10, to 10. Buying slipped from its highest in 20 days (3 chart checks stopped).
Follow ZVRA's news. Pro members can get an alert when Zevra Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 9% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and biotech stocks a median 2.1%.
| The company | Sales up 75% on the year |
| Latest filing | 8-K, Nov 3 |
After its last 4 reports it closed +10.2% on average, higher 3 of 4 times.
CEO Neil F. McFarlane sold 20,000 shares on Oct 12, under a planned sale. 12 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ZVRA scores 10 today, against a median of 6 over its last 20 recorded sessions.
ZVRA is #45 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 45 |
Expected to report Mon Mar 8, after the close (in 118 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $37.8M, 45% more than a year ago.
“$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Miplyffa | $34M | $30.2M | $22.4M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)
No outlook figures read from this release.
“In Q3 2026, the Company recognized $5.1 million in noncash income due to fair value adjustments related to warrant and contingent value rights (CVR) liability compared to $(5.5) million of noncash expense in Q3 2025.”
From its results filing (SEC filing · Nov 3)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +2.6% | +8.9% | +16.2% |
| Aug 5, 2026 | +7.4% | +12.8% | +8.6% |
| May 6, 2026 | -3.5% | -2.2% | -1.2% |
| Mar 9, 2026 | +20.1% | +21.3% | +8.2% |
Sales grew in five of the last seven years, to $106M in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 61.4, MACD above signal, above both averages. Not scored.
One insider sold $138K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ZVRA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
“Our industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
ZVRA scores 10 today, which Breakaway calls Average. It is #45 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 9% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and biotech stocks a median 2.1%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ZVRA scores 10 today, which Breakaway calls Average (6 to 10). That is #45 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ZVRA's 10.
One insider sold $138K across 1 filing in the last 6 months. No open-market buys on record. The newest is Corey Michael Watton, Director, who sold $138K on Aug 10.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.